Research programme: carbon monoxide based therapeutics - Hillhurst Biopharmaceuticals

Drug Profile

Research programme: carbon monoxide based therapeutics - Hillhurst Biopharmaceuticals

Alternative Names: HBI 002; HBI 137

Latest Information Update: 30 May 2016

Price : $50

At a glance

  • Originator Hillhurst Biopharmaceuticals
  • Class Inorganic carbon compounds
  • Mechanism of Action Heme oxygenase 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries; Multiple sclerosis; Sickle cell anaemia
  • Research Inflammation

Most Recent Events

  • 24 May 2016 Hillhurst Biopharmaceuticals receives SBIR grant from National Heart, Lung and Blood Institute (NHLBI) for HBI 002 development at preclinical stage in Sickle cell disease
  • 01 Dec 2015 Early research in Inflammation in USA (IV)
  • 01 Dec 2015 Preclinical trials in Sickle cell anaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top